Analysis of Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint - aVenture Research
PR Newswire
Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint
HANGZHOU, China, SHANGHAI and BOSTON, Nov. 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), today announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Group Limited ("Simcere") for zemprocitinib, a highly selective, oral, second-generation JAK1 inhibitor independently developed by Lynk Pharmaceuticals. Under the collaboration, Simcere will obtain exclusive commercialization rights for zemprocitinib in Chinese Mainland, Mac